4.8 Article

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

期刊

CELL
卷 166, 期 4, 页码 963-976

出版社

CELL PRESS
DOI: 10.1016/j.cell.2016.06.056

关键词

-

资金

  1. Cancer Center Support grant [5P30CA045508, P30CA008748]
  2. CSHL Association
  3. NIH [5P30CA45508-26, 5P50CA101955-07, 1U10CA180944-01, 5U01CA168409-3, 1R01CA190092-01, AG040020, CA152559, R01 CA159222]
  4. Carcinoid Foundation
  5. PCUK
  6. David Rubinstein Center for Pancreatic Cancer Research at MSKCC
  7. Stand Up to Cancer/KWF
  8. STARR Foundation [I7-A718]
  9. DOD [W81XWH-13-PRCRP-IA]
  10. Precision Medicine Research Associates
  11. Damon Runyon Cancer Research Foundation [DRG-2165-13]
  12. Human Frontier Science Program [LT000190/2013]
  13. Cancer Research Society
  14. CCSRI [702317]
  15. Canadian Institute of Health Research
  16. Swedish Research Council [537-2013-7277]
  17. Sociedad Espanola de Oncologia Medica (SEOM)
  18. Hope Funds for Cancer Research Fellowship

向作者/读者索取更多资源

Pancreatic cancer is a deadly malignancy that lacks effective therapeutics. We previously reported that oncogenic Kras induced the redox master regulator Nfe2l2/Nrf2 to stimulate pancreatic and lung cancer initiation. Here, we show that NRF2 is necessary to maintain pancreatic cancer proliferation by regulating mRNA translation. Specifically, loss of NRF2 led to defects in autocrine epidermal growth factor receptor (EGFR) signaling and oxidation of specific translational regulatory proteins, resulting in impaired cap-dependent and cap-independent mRNA translation in pancreatic cancer cells. Combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据